Abstract |
Treatment paradigms in advanced hormone receptor (HR)-positive breast cancer were substantially transformed with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) approval. The addition of these drugs to endocrine treatment profoundly improved progression-free and overall survival. Additionally, other important endpoints, such as the response rate, time to chemotherapy, and a delay in quality of life deterioration, were positively impacted by CDK4/6 inhibitors' addition to the treatment of advanced HR-positive breast cancer. This review article will summarize current knowledge on CDK4/6 inhibitors in clinical practice for advanced HR-positive metastatic breast cancer, as well as describe recent efforts to more precisely characterize mechanisms of sensitivity and resistance to these drugs, both on the molecular and clinical characterization level.
|
Authors | Debora de Melo Gagliato, Antonio C Buzaid, Jose Manuel Perez-Garcia, Antonio Llombart, Javier Cortes |
Journal | Cancers
(Cancers (Basel))
Vol. 12
Issue 9
(Sep 01 2020)
ISSN: 2072-6694 [Print] Switzerland |
PMID | 32882980
(Publication Type: Journal Article, Review)
|